Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03897881 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion dates: Nov 30, 2032 to Nov 21, 2032v18
  2. Primary and study completion dates: Sep 9, 2029 to Nov 30, 2032
    • Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 22 to 23
    v17
  3. Secondary endpoints: details revised at 3 of 3 entriesv16
  4. Site contacts updated at 4 of 22 sitesv15
  5. Study sites: 21 to 22v14
Show 12 earlier versionsHide 12 earlier versions
  1. Enrollment target: 257 to 267v13
  2. Study sites: 22 to 21v12
  3. Trial status: Active, Not Recruiting to Recruitingv11 Show 5 more changesShow less
    • Enrollment target: 157 to 257
    • Primary and study completion dates: Sep 29, 2024 to Sep 9, 2029
    • Interventions: Pembrolizumab (Biological), mRNA-4157 (Biological) to Pembrolizumab (Biological), mRNA-4157 (Drug)
    • Secondary endpoints: details revised at 3 of 3 entries
    • Site details revised at 22 of 22 sites
  4. Primary completion date: Jun 30, 2022 to Sep 29, 2024
    • Study completion date: Jun 30, 2024 to Sep 29, 2024
    v10
  5. Re-verified, no change to tracked fieldsv9
  6. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 150 to confirmed 157
    • Site details revised at 22 of 22 sites
    v8
  7. Re-verified, no change to tracked fieldsv7
  8. Primary endpoint revised
    • Eligibility criteria expanded, about 17 words
    • Secondary endpoints: 4 to 3
    • Study title revised
    v6
  9. Primary completion date: Dec 2021 to Jun 30, 2022
    • Study sites: 16 to 22
    • Study completion date: Dec 2023 to Jun 30, 2024
    v5
  10. Study sites: 17 to 16v4
  11. Site details revised at 1 of 17 sitesv3
  12. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 17
    • Start date changed from estimate of Jul 2019 to Jul 18, 2019
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Moderna
49 trials monitored
See 3 trials at risk
Melanoma
1,092 trials monitored
See 60 trials at risk
The purpose of this study is to assess whether postoperative adjuvant therapy with mRNA-4157 and pembrolizumab improves recurrence free survival (RFS) compared to pembrolizumab alone in participants with complete resection of cutaneous melanoma and a high risk of recurrence.
Trial Details
NCT Number NCT03897881
Lead Sponsor ModernaTX, Inc.
Collaborators: Merck Sharp & Dohme LLC
Conditions
(from sponsor)		 Melanoma
Related terms Melanoma
Enrollment 267 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov